<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02048072</url>
  </required_header>
  <id_info>
    <org_study_id>ANSG 1.8</org_study_id>
    <nct_id>NCT02048072</nct_id>
  </id_info>
  <brief_title>Evaluation of the Autonomic Nervous System During First-dosing With 0.5mg of Fingolimod (Gilenya) in Patients With Relapsing-remitting MS</brief_title>
  <acronym>ANSG</acronym>
  <official_title>Funktionelle Evaluation Des Autonomen Nervensystems im Zusammenhang Mit Der Erstmaligen Einnahme Von 0,5mg Fingolimod (Gilenya) Bei Patienten Mit schubf√∂rmig Verlaufender Multipler Sklerose</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jochen Vehoff</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cantonal Hospital of St. Gallen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to primarily evaluate the impact of Gilenya (Fingolimod) on the
      autonomic nervous system in patients being treated for the first time with Gilenya
      (Fingolimod). Effects on the cardiovascular system will be studied as well. The study is
      conducted to answer the question, if, and if yes, what impact the treatment with Gilenya
      (Fingolimod) has on the autonomic nervous system. To our knowledge little is known about the
      effects of Gilenya (Fingolimod) on the autonomic nervous system. We do know of rare, but
      potentially clinically and therapeutically relevant cardiovascular adverse events of Gilenya
      (Fingolimod). From a scientific point of view the mechanisms by which this is mediated are of
      interest. Maybe a better understanding of these mechanisms might even be of clinical
      relevance (e.g. risk stratification).

      The impact of Gilenya (Fingolimod) on the autonomic nervous system is quantitavely measured,
      using a state-of-the-art technique. Non-invasive blood pressure measurement is performed with
      the Finometer Pro (Finapres Medical Systems, NL) under different paradigms (breathing at
      rest, deep breath, valsalva maneuver, active standing). In addition the sympathetic skin
      reaction is performed. The non-invasive blood pressure measurements are done by continuous,
      plethysmographic blood pressure measurement at the index finger, while the patient is
      performing the tasks mentioned above. By interpreting the blood pressure curve, heart rate
      and blood pressure variability are calculated. The sympathetic skin reaction consists of
      measuring the change of electric conductibility of the skin (palms and soles) after an
      electric stimulus of a peripheral nerve. These parameters allow to assess the functionality
      of four important autonomic functional systems (orthostasis, sympathetic adrenergic,
      sympathetic cholinergic, parasympathetic cholinergic). Normative data has been acquired in
      our lab.

      Our hypothethis is, that there will be a change of heart rate variability at t4,5h compared
      to baseline (t0) for the parameter &quot;RMSSD&quot; under &quot;normal breathing&quot;.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>RMSSD Normal Breathing</measure>
    <time_frame>t-4,5 hours</time_frame>
    <description>Root Mean Square of the Successive Differences (RMSSD) is one of a few time-domain tools used to assess heart rate variability, the successive differences being neighboring RR or pulse intervals.
It is calculated as the square root of the mean of the squares of the successive differences between adjacent RR intervals or pulse intervals.
In this study pulse intervals were measured non-invasively during five minutes, while subjects were supine, breathing regularly.
Measurements were done at two timepoints t=0 and t=4,5hours. RMSSD was compared between these two timepoints.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Multiple Sclerosis</condition>
  <condition>Autonomic Nervous System Dysfunction</condition>
  <arm_group>
    <arm_group_label>Gilenya</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Autonomic testing during first dose adminstration of Gilenya.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gilenya</intervention_name>
    <description>Autonomic testing during first dose administration of Gilenya.</description>
    <arm_group_label>Gilenya</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  indication for treatment with Gilenya according label

          -  treatment with Gilenya intended

          -  no contraindications for the treatment with Gilanya

          -  all safety-aspects have been fullfilled

          -  age between 18 and 60 years

          -  written consent is given

        Exclusion Criteria:

          -  relapse during the last 30 days befor randomization

          -  steroids within 30 days before randomization

          -  heart rhythm disturbance

          -  new or currently changed dose (last 4 weeks) of bata-blockers, calcium antagonists,
             antidepressants or antiarrhythmics

          -  diabetes mellitus

          -  polyneuropathy

          -  missing consent

          -  pregnancy

          -  lactation period
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jochen Vehoff, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cantonal Hospital of St. Gallen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cantonal Hospital St. Gallen</name>
      <address>
        <city>St. Gallen</city>
        <state>SG</state>
        <zip>9000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 27, 2014</study_first_submitted>
  <study_first_submitted_qc>January 27, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 29, 2014</study_first_posted>
  <results_first_submitted>March 1, 2016</results_first_submitted>
  <results_first_submitted_qc>March 30, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 29, 2016</results_first_posted>
  <last_update_submitted>March 30, 2016</last_update_submitted>
  <last_update_submitted_qc>March 30, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Cantonal Hospital of St. Gallen</investigator_affiliation>
    <investigator_full_name>Jochen Vehoff</investigator_full_name>
    <investigator_title>Dr. med. Jochen Vehoff</investigator_title>
  </responsible_party>
  <keyword>relapsing remitting</keyword>
  <keyword>multiple sclerosis</keyword>
  <keyword>fingolimod</keyword>
  <keyword>Gilenya</keyword>
  <keyword>autonomic nervous system</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fingolimod Hydrochloride</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>First patient in: 21.08.2013 Last patient out: 16.06.2015</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Gilenya</title>
          <description>Gilenya 0.5mg p.o. once daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Gilenya</title>
          <description>Gilenya 0.5mg p.o. once daily</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="33"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37.57" spread="12.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Switzerland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>EDSS</title>
          <description>Expanded Disability Status Scale Range 0-10 (no disability - death due to Multiple Sclerosis)</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.75" spread="1.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71.18" spread="13.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="168.72" spread="7.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body temperature</title>
          <units>¬∞C</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36.58" spread="0.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>RMSSD Normal Breathing</title>
        <description>Root Mean Square of the Successive Differences (RMSSD) is one of a few time-domain tools used to assess heart rate variability, the successive differences being neighboring RR or pulse intervals.
It is calculated as the square root of the mean of the squares of the successive differences between adjacent RR intervals or pulse intervals.
In this study pulse intervals were measured non-invasively during five minutes, while subjects were supine, breathing regularly.
Measurements were done at two timepoints t=0 and t=4,5hours. RMSSD was compared between these two timepoints.</description>
        <time_frame>t-4,5 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Gilenya</title>
            <description>Gilenya 0.5mg p.o. once daily</description>
          </group>
        </group_list>
        <measure>
          <title>RMSSD Normal Breathing</title>
          <description>Root Mean Square of the Successive Differences (RMSSD) is one of a few time-domain tools used to assess heart rate variability, the successive differences being neighboring RR or pulse intervals.
It is calculated as the square root of the mean of the squares of the successive differences between adjacent RR intervals or pulse intervals.
In this study pulse intervals were measured non-invasively during five minutes, while subjects were supine, breathing regularly.
Measurements were done at two timepoints t=0 and t=4,5hours. RMSSD was compared between these two timepoints.</description>
          <units>milliseconds</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.10" lower_limit="2.56" upper_limit="25.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.02</p_value>
            <method>t-test, 1 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Gilenya</title>
          <description>Gilenya 0.5mg p.o. once daily</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>AV-Block Mobitz II / AV-Block III¬∞</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>worsening of neuropsychological symptoms</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>exacerbation of migraines</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jochen Vehoff</name_or_title>
      <organization>Cantonal Hospital of St. Gallen</organization>
      <phone>0041714941111</phone>
      <email>jochen.vehoff@kssg.ch</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

